IntroductionThis Datamonitor study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, the UK, France, Germany, and India.
It is based on the results of Datamonitor's Business Trends primary research, conducted in Q3 and Q4 2007, with a total of 150 life science companies.ScopeIn-depth interviews with 150 pharmaceutical and biotechnology companiesGeographic coverage includes: the US, the UK, France, Germany, and IndiaThe study focuses on the business challenges, IT budget outlook, and the degree to which the market has adopted EDC and SOA solutionsRespondents included IT decision-makers such as CIOs and CTOsHighlightsIT vendors targeting the life science market must demonstrate deep industry knowledge and have high expertise in their specialty product.Companies in the life science industry must build and maintain their product pipeline to compete with generic drug manufacturers.
To achieve this, companies are beginning to change their business models, albeit slow, and are investing more money into technology solutions.Pharmaceutical and biotechnology companies have several goals that affect their IT strategies, including achieving or maintaining regulatory compliance, raising efficiency, and aligning IT with overall business objectives.Reasons to PurchaseValidate your market messaging and positioning in the life science industryCompare pharmaceutical and biotechnology IT purchasing plans across geographiesIdentify emerging areas of concern for pharmaceutical and biotechnology companies